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This position paper focusses on the pathophysiology, diagnosis and management of women diagnosed with a cardiomyopathy, or at risk
of heart failure (HF), who are planning to conceive or present with (de novo or previously unknown) HF during or after pregnancy. This
includes the heterogeneous group of heart muscle diseases such as hypertrophic, dilated, arrhythmogenic right ventricular and non-classified
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cardiomyopathies, left ventricular non-compaction, peripartum cardiomyopathy, Takotsubo syndrome, adult congen-
ital heart disease with HF, and patients with right HF. Also, patients with a history of chemo-/radiotherapy for cancer
or haematological malignancies need specific pre-, during and post-pregnancy assessment and counselling. We sum-
marize the current knowledge about pathophysiological mechanisms, including gene mutations, clinical presentation,
diagnosis, and medical and device management, as well as risk stratification. Women with a known diagnosis of a
cardiomyopathy will often require continuation of drug therapy, which has the potential to exert negative effects on
the foetus. This position paper assists in balancing benefits and detrimental effects.
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Graphical Abstract
Specific cardiomyopathy and pregnancy diagnostic algorithm. ECG, electrocardiogram; MRI, magnetic resonance imaging; NT-proBNP, N-terminal
pro-B-type natriuretic peptide.
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Introduction
The number of women with heart disease who become pregnant is
increasing, thereby contributing to a significant morbidity or mor-
tality due to heart failure (HF), peripartum thromboembolic events
and arrhythmias.1 Due to advances in genetic testing, there are also
more men and women known to have a mutation associated with a
cardiomyopathy and HF2 seeking pre-conception counselling. Also,
patients with a history of cardiotoxic therapies (e.g. for malignant
conditions), but without HF before pregnancy, need specific advice
and risk stratification. Clear guidelines/directions how to counsel
those patients before, during or after pregnancy are lacking.
The aetiology of cardiomyopathies occurring de novo, in asso-
ciation with pregnancy, is diverse (Graphical Abstract). Cardiomy-
opathies are neither very rare nor common, but they are important
as they may cause severe complications, contributing substantially
to maternal morbidity and mortality during pregnancy, in the
immediate peripartum period and up to several months thereafter.


























.. also commonly have arrhythmias which need specific manage-
ment, including device therapy. Very little information and few
recommendations have been published in this important field.
Women with a known diagnosis of a cardiomyopathy or pre-
senting with (de novo) HF during/after pregnancy, will often require
continuation of medical therapy, which has the potential to exert a
negative effect on the foetus, meaning that adequate and appro-
priate treatment is vital. Accurate information on the foetal
effect of medication is crucial to weigh the advantages of treat-
ing the mother against the possible long-lasting negative effects
on the child.
Hypertensive HF, an important and prevalent complication
during pregnancy, is not covered by this position paper. During
pregnancy hypertensive emergencies with increased risk for the
foetus can develop, including pulmonary oedema at lower levels of
blood pressure compared with non-gravid women. Treatment of
hypertension can prevent the progression to HF and decrease the
risk of maternal and foetal complications.1
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This position paper refers to other recently published papers,1,3
but will fill important gaps in knowledge and is, therefore, a
much-needed reference for cardiologists, specialist physicians,
obstetricians, neonatologists, anaesthetists, intensivists, cardiotho-
racic surgeons, genetic counsellors and others.
Pathophysiology of heart failure
in genetic, idiopathic
and cardiotoxic therapy-related
cardiomyopathies and its impact
on the peripartum period
Recent studies linked pregnancy to a stress model (physiological
changes during pregnancy are summarized in online supplemen-
tary Table S1) which may unmask a pre-existing genetic and/or
acquired cardiomyopathy. These women are asymptomatic prior
to pregnancy but develop HF and arrhythmias during pregnancy or
postpartum due to volume overload and humoral stress. Frequent
mutations, i.e. likely pathologic and pathologic gene variants, mostly
heterozygous or compound heterozygous, have been observed
in desmoplakin (DSP), carnitine palmitoyltransferase 2 (CPT2), TTN
DSP MYH7, LMNA, BAG3, TNNT2, TNNC1, PLN, ACTC1, NEXN,
TPM1, and VCL.4–6 Furthermore, metabolic factors play a role;
under physiological circumstances, maternal lipid metabolism is
increased during the last trimester of pregnancy and normalizes
after delivery. Induced pluripotent stem cells from peripartum car-
diomyopathy (PPCM) patients revealed that lipid metabolism was
widely affected.7
Pregnancy also emerges as the possible second hit that may trig-
ger late onset cardiomyopathy after cardiotoxic cancer treatment.
Women who experienced chemotherapy-induced cardiotoxicity
have a higher risk for developing HF during pregnancy.8 Moreover,
previous cardiotoxic cancer therapies may trigger PPCM, even in
the absence of left ventricular (LV) dysfunction immediately after
cancer therapies.9,10 In the same collective of PPCM patients with
cancer, gene variants associated with an increased risk for cancer
predisposition syndrome, especially in the DNA damage response
pathway (DDR), were observed suggesting potential connections
to pregnancy-associated cardiomyopathy as a form of late car-
diotoxicity due to anticancer treatment.6 Gene variants associated
with impaired DDR may affect stress tolerance and repair ability of
the heart. Mutations in the DDR genes ataxia telangiectasia mutated
(ATM) and breast cancer 1 (BRCA1) not only increase the risk for
cancer, but may also promote cardiomyopathies and HF per se,11–14
and may also increase the risk for late cardiotoxicity.
Managing acute heart failure
in patients during pregnancy or
postpartum
If acute HF (AHF) develops in a pregnant patient, immediate refer-
ral to an intensive care unit and assessment of HF severity and



















































































.. tests including natriuretic peptides (NPs), urgent echocardiography
is recommended to detect left and/or right HF, valvular abnormal-
ities, etc. To ensure rapid diagnosis, decision-making and therapy,
a pre-specified interdisciplinary task force and management algo-
rithm are recommended (Figure 1).1,3 If stabilization of the patient
is possible, delivery may be delayed especially in order to avoid
severe prematurity of the baby.
Patients in cardiogenic shock or severe AHF requiring inotropes
or vasopressors should be transferred early to a tertiary centre
capable of providing mechanical circulatory support (MCS) and
ventricular assist devices.15 In these patients, urgent delivery by
caesarean section (irrespective of gestation) should be considered
with MCS available. PPCM patients seem to be especially sensitive
to the toxic effects of beta-adrenergic agonists, which should
be avoided whenever possible; levosimendan may be used as
alternative inotropic drug.15,16
In patients with stabilized or subacute AHF, management
goals are similar to AHF in non-pregnant patients, but feto-
toxic agents [angiotensin-converting enzyme (ACE) inhibitors,
angiotensin receptor blockers, angiotensin receptor–neprilysin
inhibitors (ARNI), mineralocorticoid receptor antagonists] should
be avoided.15–17 Loop diuretics should be used in patients
with symptoms or signs of congestion, with foetal monitoring
due to concerns about placental blood flow. Nitrates are safe
in pregnancy. After stabilization, initiation and up-titration of
beta-blockers should be performed with caution. If high resting
heart rate persists in the presence of beta-blockade, or intolerance
thereof, treatment with ivabradine may be initiated in patients not
pregnant or breastfeeding.
The European Society of Cardiology (ESC) guidelines on car-
diac disease in pregnancy1 recently added a recommendation on
the use of bromocriptine in patients with PPCM (class IIb, level B).
Bromocriptine (2.5 mg once daily) for 1 week may be considered in
uncomplicated cases, whereas prolonged treatment (2.5 mg twice
daily for 2 weeks, then 2.5 mg once daily for 6 weeks) may be
considered in patients with ejection fraction <25% and/or cardio-
genic shock.1,15,18 Bromocriptine treatment must always be accom-
panied by anticoagulation with heparin in at least prophylactic
dosages.1
Standard indications for anticoagulation in AHF apply during
and after pregnancy.1 In pregnant or postpartum AHF patients
with very low ejection fraction, therapeutic anticoagulation may
be considered to prevent thromboembolic events.
Managing pregnancies in patients
with chronic heart failure
Prevalence of HF was 11% in a cohort of 5739 pregnancies
in patients with congenital, ischaemic and valvular heart disease
and cardiomyopathies.1,19 Any cardiac event, including HF symp-
toms, admission to hospital, intensive care unit, respiratory failure,
arrhythmias, and maternal death, in pregnant patients with chronic
HF during pregnancy is devastating.19
Patients may already be known to have HF and wish to become
pregnant or may present during pregnancy due to the increasing
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Management of acute heart failure (HF) during/after pregnancy: rapid interdisciplinary workup and treatment of the mother
and foetus. ACE-I, angiotensin-converting enzyme inhibitor; AHF, acute heart failure; ARB, angiotensin receptor blocker; ARNI, angiotensin
receptor–neprilysin inhibitor; ECG, electrocardiogram; HR, heart rate; LVAD, left ventricular assist device; LVEF, left ventricular ejection
fraction; MR, mineralocorticoid receptor; NIV, non-invasive ventilation; PDA, peridural anaesthesia; PPCM, peripartum cardiomyopathy; SBP,
systolic blood pressure; ScvO2, central venous oxygen saturation; SpO2, blood oxygen saturation; VA ECMO, veno-arterial extracorporeal
membrane oxygenation; WCD, wearable cardioverter-defibrillator. Modified from Regitz-Zagrosek et al.1
haemodynamic burden. Distinguishing symptoms and signs of nor-
mal pregnancy from HF demands careful clinical assessment and
investigation.20
Heart failure also places pregnant women at high risk for
pre-term labour and delivery. Babies born to women with HF
are at risk for prematurity, small-for-gestational-age status,
infant respiratory distress syndrome, and foetal and neonatal
death.1,21
Actions needed in order to minimize morbidity and possible
mortality in pregnant HF patients are summarized in Figure 2.
Management of HF and arrhythmias in peripartum women should
be according to the underlying cardiac disease and following
established guidelines.1 Pre-pregnancy management must include
modification of existing HF medications to avoid teratogenicity
and minimize harm to the foetus. ACE-inhibitors, angiotensin























.. ivabradine and sodium–glucose co-transporter 2 inhibitors
are contraindicated during pregnancy as they are associated
with a high risk of adverse foetal effects in all trimesters.3,22
They should be stopped prior to conception, with close clinical
and echocardiographic monitoring. If these drugs have been
inadvertently taken during the first trimester, they should be
stopped, and the patient monitored (maternal echocardiography
and foetal ultrasound) closely. Beta-adrenergic blocking agents are
generally safe in pregnancy but are associated with increased rates
of foetal growth restriction. Loop and thiazide diuretics can be
continued for the treatment of pulmonary congestion.
Sub-pulmonary ventricular failure (failure of the ventricle – right
or left – which serves the pulmonary circulation) may also occur,
especially in patients with pulmonary arterial hypertension. Bed
rest and fluid balance with diuretics and inotropes could be used.
In cases of pulmonary arterial hypertension, targeted therapy
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Management of congestive heart failure in pregnancy. WHO; World Health Organization.
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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with phosphodiesterase-5 inhibitors or prostaglandins may be
considered.23–26
Iron deficiency is common in heart failure, is often overlooked
and has an independent adverse effect on cardiac function and
for maternal health.27–29 Also in pregnant women, iron deficiency
(both with and without anaemia) is highly prevalent.30,31 Iron
deficiency reveals unfavourable consequences on the health status
of the foetus and the mother.31–33 Depleted iron compromises
erythropoiesis, but also triggers thrombosis, coagulopathy and
thromboembolic events, compromises energy metabolism in foetal
and maternal tissues, impairing the functioning of myocardium and
other types of muscles.31–35 The effects of oral and intravenous
iron supplementation in this particular patient population are under
investigation.
Natriuretic peptides for screening
and risk stratification to help
ensure appropriate referral
Natriuretic peptide [B-type natriuretic peptide (BNP), N-terminal
proBNP (NT-proBNP)], and mid-regional pro-atrial NP] concen-
trations are quantitative plasma biomarkers of the presence and
severity of haemodynamic cardiac stress and HF.36
As the severity of HF is a strong predictor of the risk for
cardiac complications in patients with cardiac disorders in general
as well as in women during and after pregnancy in particular,
quantifying the severity of HF using NP measurements may facilitate
the detection of patients at high risk for cardiac complications
and help appropriate referral.37–39 During normal pregnancies in
healthy women, NP concentrations remain in the normal range.39,40
Pre-eclampsia and deterioration of cardiomyopathy/HF due to
other causes will lead to an increase in NPs.39–41 NP concentration
should be checked in women diagnosed with a cardiomyopathy
before pregnancy, monitored e.g. once every trimester and in case
symptoms of possible deterioration such as dyspnoea occur.39–41
Exercise testing
Physiological exercise testing should be performed when pregnancy
is planned in patients with known or previous HF but also in
patients at risk for HF, e.g. with adult congenital heart disease
(ACHD) or after previous chemo-/radiotherapy for malignant
disease. Submaximal exercise testing (80% of predicted maximal
heart rate) may also be performed in asymptomatic patients with
suspected heart disease if already pregnant without increased risk
of spontaneous miscarriage.
Delivery in a woman presenting
with heart failure
The safe delivery of a woman presenting in HF is a challenge requir-
ing the input of a multidisciplinary team to achieve the best out-



















































































.. gestational age at presentation, whether there is a reversible under-
lying reason for HF and, in its absence, the response to medical
measures. Prophylactic and, in some circumstances such as per-
sisting arrhythmia and intracardiac thrombosis, therapeutic antico-
agulation should be given. Unless there is a reversible cause for HF,
such as arrhythmia, anaemia or infection, then after optimization
of therapy, delivery should be considered, ideally from 32 weeks,
when foetal survival without major disability is expected, or earlier,
including termination of pregnancy, when the response to medi-
cal therapy is suboptimal, the precipitating problem is irreversible
and/or there is a significant risk to the life or long-term health of
the woman of continuing the pregnancy.
Most often delivery will be by caesarean section, as advised
by the ESC guidelines.1 Only occasionally vaginal delivery may
be possible; in either circumstance, meticulous attention to
fluid balance is key, particularly in the context of post-partum
haemorrhage.
If vaginal delivery is attempted, effective pain relief is essential and
an instrumental delivery, without prior maternal effort, is likely to
be the safest approach. Vaginal delivery is associated with less blood
loss and lower risk of infection, venous thrombosis, and embolism,
and should be advised for most women. For the third stage careful
use of uterotonics, avoiding agents like ergometrine and carboprost
and the early or even prophylactic use of mechanical approaches,
including brace suture and balloon compression, for the manage-
ment of post-partum haemorrhage are advised. Once delivery is
achieved and after the immediate peripartum period, important
consideration is effective contraception. Progesterone-based con-
traception methods have the advantage of not increasing the risk
of thrombosis and are the most effective.1
Specific cardiomyopathies
There is a heterogeneous group of heart muscle diseases such as
PPCM, hypertrophic cardiomyopathy (HCM), dilated cardiomy-
opathy (DCM) and LV non-compaction (LVNC) (Graphical Abstract)
as well as others such as arrhythmogenic right ventricular car-
diomyopathy (ARVC), Takotsubo syndrome (TTS), ACHD with HF.
Peripartum cardiomyopathy
Peripartum cardiomyopathy is HF that occurs towards the end of
pregnancy or in the months following delivery.42 Major geographical
variations in incidence exist (1–100 in 10 000 live births),42 com-
pounded by the fact that patients are usually only diagnosed when
they have severe symptoms43 – raising the possibility that those
with less severe presentation might go undiagnosed. A high index of
suspicion is encouraged from midwives and obstetric teams. Inves-
tigations for possible PPCM should include an electrocardiogram
and/or BNP (and echocardiography if either of these are abnor-
mal). As there are no specific biomarkers for PPCM established
to date, differentiation from other cardiomyopathies is not eas-
ily possible.3 Recently, circulating plasminogen activator inhibitor-1
and miR-146a have been suggested as potential specific biomarkers
for PPCM but are not used yet in clinical practice.44
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Peripartum cardiomyopathy is associated with a mortality rate
of around 6% at 6 months, but has a high chance of myocardial
recovery of around 50% reported up to 3 years after diagnosis.43,45
A management plan should be formulated, taking into account
the wellbeing of the mother and baby.3 For those who are still
pregnant, a delivery plan will involve obstetricians, paediatricians,
cardiologists and cardiac surgeons (in case MCS is necessary).
Medical therapy pre-delivery invariably involves decongestion
with diuretics but should avoid drugs that are deleterious to the
foetus (see Table 3 in Bauersachs et al.3). If PPCM is diagnosed
post-delivery there are several key aspects of management. Ther-
apy should include drugs that are safe during lactation3 or, if
not breast-feeding, medical therapy should follow conventional
guideline-directed HF therapy. Anticoagulation (HF and pregnancy
are both pro-coagulant conditions, and the rate of thromboem-
bolic events is relatively high)45 and bromocriptine should be
considered.1,3,18,46 Implantable cardioverter-defibrillators and
cardiac resynchronization therapy can have a role, but care
should be taken to avoid implantation in women who are likely
to recover on conventional medical therapy.3 Prior to dis-
charge, counselling should include advice about contraception
and the risk of subsequent pregnancies.47 When and whether
to stop medical HF therapy when myocardial recovery is seen
is uncertain.48 The risk of subsequent pregnancies depends
upon whether or not the woman has experienced myocardial
recovery (usually defined as a LV ejection fraction >50%).47
For those who have recovered, the rate of death is <1% and
a risk of recurrent HF is around 10% but for those who have
not recovered, the risk of death is around 10% and recurrent
HF 25–50%.47
Hypertrophic cardiomyopathy
The observed incidence of HCM in pregnancy is <1:1000. Maternal
mortality is low (0.5%) and complications or worsening of symp-
toms occur in 29% of cases.1,49 Foetal mortality is comparable to
the general population. However, the risk of premature birth is
increased (26%). Risk is higher in women who are symptomatic
before pregnancy or exhibit diastolic dysfunction, severe LV out-
flow tract obstruction or arrhythmia. Symptoms and medication
before pregnancy are also risk factors for maternal cardiac events.
Echocardiography is crucial for diagnosis.
Women with HCM should be risk stratified according to the ESC
guidelines for cardiac disease in pregnancy according to the modi-
fied World Health Organization (WHO) class.1 Women in WHO
class II should be assessed during each trimester and those in class
III assessed monthly or bi-monthly. A recent randomized study on
the effectiveness of implanted cardiac rhythm recorders for detect-
ing arrhythmias in pregnant women with structural heart disease
suggests that those devices could be considered in HCM facilitat-
ing early detection of arrythmia or re-assurance of the mother and
avoiding harm-full medication.3,50 Beta-blockers should be contin-
ued if they are already being taken and foetal growth monitored.
Beta-blockers should be started when new symptoms occur, for
rate control in atrial fibrillation and to suppress ventricular arrhyth-



















































































.. considered for poorly tolerated persistent atrial fibrillation. Thera-
peutic anticoagulation is recommended for those with paroxysmal
or persistent arrhythmias.
Low-risk cases may proceed with vaginal delivery. Caesarean
section should be considered in patients with severe LV outflow
tract obstruction, pre-term labour while on oral anticoagulation
or severe HF. In the Registry Of Pregnancy And Cardiac dis-
ease (ROPAC), only 5% of patients required emergency caesarean
section.49 During delivery, heart rate and rhythm should be moni-
tored in patients with a high risk of developing arrhythmias.
Arrhythmogenic right ventricular
cardiomyopathy
Arrhythmogenic right ventricular cardiomyopathy is a rare inher-
itable chronic and progressive cardiomyopathy. Its prevalence
is 0.02–0.05%, but it is one of the leading causes of sudden
cardiac death in young women.51,52 For women not having a
cardioverter-defibrillator implant before pregnancy,53 ARVC
severity score is highly predictive for the occurrence of ventricular
arrhythmias, and echocardiographic and signal-averaged ECGs
are markers of ventricular arrhythmias. Ventricular arrhythmia
and disease progression in ARVC are worsened by vigorous
exercise.54 Pregnancy could be regarded as a state of prolonged
haemodynamic stress and might affect disease progression in
ARVC. However, in a recently published large population, preg-
nancy did not affect cardiac structure or function in ARVC,
supporting previous reports of well-tolerated pregnancies in this
patient group.52 Given the exacerbation induced by exercise, then
vaginal delivery with an epidural and assisted delivery is likely to
be the safest approach.
Moreover, serious cardiac symptoms did not worsen during
pregnancy, number of pregnancies was not associated with arrhyth-
mic events, and higher number of pregnancies was not associated
with worse outcome in women with ARVC. Thus, the long-term
effect of pregnancy is well tolerated, and pregnancy appears rela-
tively safe in women with ARVC.
Nevertheless, since data are still scarce, we suggest that these
patients should be referred to an experienced centre for structured
follow-up from early pregnancy until after delivery.
Left ventricular non-compaction
cardiomyopathy
Left ventricular non-compaction is a rare congenital heart dis-
ease (CHD), which is characterized by hypertrabeculation of the
myocardium with deep intertrabecular recesses, and a subset of
patients develop LV dysfunction, with an increased risk of throm-
boembolic events. During normal pregnancy, there is a transient
increase in LV trabeculation which occurs in one quarter of women.
This makes diagnosis of LVNC during pregnancy challenging.55
Pregnancy in LVNC is often complicated by HF and arrhythmias,
but no mortality during pregnancy has been reported.56 There
is no specific treatment, but anticoagulation is recommended for
patients with LVNC and a history of thromboembolic events, atrial
fibrillation, intracardiac thrombi or impaired LV function.57
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Takotsubo syndrome
Takotsubo syndrome is an acute and usually reversible HF
syndrome with initial presentation similar to acute coronary
syndrome.58 Often triggered by emotional stress and much more
common in women than men, TTS is characterized by reversible
LV dysfunction with extensive apical cardiac akinesia. Cardiac func-
tion recovers almost entirely within a few days/weeks if the patient
survives the acute phase. Unfortunately, cardiac dysfunction can
be sufficiently severe to cause life-threatening complications such
as fulminant HF, cardiogenic shock, heart rupture and ventricular
fibrillation. Many aspects of TTS are incompletely understood
or characterized, and knowledge to guide optimal clinical man-
agement is limited. Treatment recommendations are based on
expert opinion. It is advisable to seek expert support in TTS
patients at high risk. Most of the reported TTS cases in pregnant
women happened after childbirth with caesarean delivery, but
TTS has also been reported in women during pregnancy. Similar
to non-pregnant patients with TTS, recovery occurred between
4 days and 3 months.59
The European task force position statement suggests classifying
TTS into lower-risk and higher-risk categories58 and to consider
ACE-inhibitor/ARNI and a beta-blocker in higher-risk groups.
However, ACE-inhibitors/ARNI are contraindicated in pregnancy
and evidence for beta-blockers is not established in TTS; these
agents should not be used in pregnant women with TTS. In severe
cases with life-threatening haemodynamic instability (lung oedema,
cardiogenic shock), MCS should be considered early in the clin-
ical course. Occasionally, thrombus formation may occur in the
dyskinetic segment. Even though a visualized thrombus mandates
anticoagulation, routine anticoagulation for dyskinesis without
thrombus is not recommended, because of the rapid resolution of
the condition.
Dilated cardiomyopathy
The term DCM encompasses acquired and inherited conditions
characterized by LV dilatation and systolic dysfunction in the
absence of significant abnormalities in loading conditions or coro-
nary artery disease.60 Causes include pathogenic gene variants
in 20–35%, and/or acquired triggers including prior viral infec-
tion, immune-mediated and drug-induced LV dysfunction.4 To date,
>50 gene mutations have been described associated with DCM
phenotype,17,61 but the genetic contribution of 12 of them has
recently been re-enforced.5
Although PPCM and DCM are considered distinct disease enti-
ties, with differentiation largely supported by the timing of pre-
sentation, they may share a genetic predisposition.62,63 When the
patient presents during the course of pregnancy, differentiation may
be challenging.4,64
Patients with pre-existing DCM receiving current disease-
modifying treatment may show substantial/complete recovery of
LV systolic function.62 However, pregnancy is poorly tolerated in
women with DCM, carrying with it the potential for significant
deterioration in LV function (depending on the residual severity



















































































.. the degree of symptoms (approximately 7% for New York Heart
Association class III or IV) and ejection fraction <40%.19,66 Signif-
icant risk factors include ejection fraction <20%, mitral regurgi-
tation, right ventricular failure, atrial fibrillation and/or hypoten-
sion. All patients with DCM who are pregnant therefore require
appropriate joint cardiac and obstetric care, since there is a high
risk of overt HF, irreversible deterioration in ventricular function
and foetal loss, as well as maternal mortality.
Standard indications for anticoagulation in DCM apply dur-
ing pregnancy, including the presence of intracardiac thrombus
and paroxysmal/persistent atrial fibrillation. The choice of the
anticoagulant agent (low molecular weight heparin or vitamin K
antagonists) will depend upon the stage of pregnancy and patient
preference.67 Non-vitamin K antagonist oral anticoagulants are not
recommended for use in pregnancy.
When a new diagnosis of DCM is made, there are potential
implications not just for the patient, but also for other blood
relatives potentially requiring clinical screening of family members
and referral to experts in cardiovascular genetics.62
Cardiac transplantation
Female patients represent around 20% of overall cardiac trans-
plants, with around 25% of these of childbearing age.68 There are
risks to the transplanted mother and foetus, but also to a foetus
whose father is a cardiac transplant recipient.69 Multidisciplinary
care is mandatory, preferably coordinated by the transplant
centre.70 Successful conception (including in vitro fertilization) and
delivery have been reported in patients with cardiac transplanta-
tion and also in patients with long-term ventricular assist devices
but data are scarce and of low quality.
Pre-conception counselling includes the risks to the mother and
the foetus including graft rejection, graft dysfunction, infection, and
teratogenicity of immunosuppressive agents. Some centres recom-
mend paternal HLA testing prior to conception, as if the donated
heart and father have the same HLA antigen, and the recipient
develops donor-specific antibodies, the risk of autograft rejection is
high.71 The reason for the indication for transplantation should also
be considered in pre-conception counselling; children of mothers
with pre-transplant CHD have up to 10% risk of congenital disease
in the foetus.72,73 Here, early foetal screening is indicated. Female
transplant patients should be advised to avoid pregnancy for at least
1 year post-transplantation, that their risk of spontaneous abortion
is around 10–20%, and that they will undergo more intense surveil-
lance of graft function during and after any pregnancy. Successful
pregnancy is most likely where there is normal graft function and no
evidence of rejection. If clinically indicated, standard investigations,
up to and including endomyocardial biopsy, should be undertaken
prior to pregnancy. In those at high risk of rejection and/or with
poor baseline graft function before pregnancy, it should be strongly
discouraged/delayed until these risks can be reduced. All medica-
tions (including immunosuppression) should be reviewed prior to
conception, with cessation/substitution of teratogenic drugs, and
close monitoring of drug levels (where their metabolism can be
altered by pregnancy, e.g. cyclosporine).
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Hypertension is the commonest maternal complication during
pregnancy and may result in foetal growth restriction and pre-term
delivery.74 Hyperemesis gravidarum may result in poor/partial
absorption of immunosuppressive medication and requires care-
ful monitoring. Venous and pulmonary thromboembolic disease is
more common in cardiac transplant recipients,75 and clinical suspi-
cion should remain high. All immunosuppressive medications enter
the foetal circulation, thus the management of immunosuppression
in the pregnant post-transplant recipient should be conducted by
the experts. As all immunosuppressive agents are excreted into
breast milk with unknown long-term effects, breastfeeding is not
recommended.
Pregnancy, cancer and heart
failure
Cardiovascular risk during pregnancy
in female cancer survivors
There is a growing population of female cancer survivors of
child-bearing age following treatment and cure of a malignancy
as a child or young adult. Curative treatment pathways fre-
quently include cardiotoxic therapies, including anthracycline (AC)
chemotherapy (∼60% of all paediatric malignancies) and/or radi-
ation to the chest.76 There is a sixfold increased risk of HF
at long-term follow-up in paediatric cancer survivors who were
treated with AC chemotherapy.77 The risk is dose-related for both
AC and radiation therapy, and lifelong cardiomyopathy surveillance
in cancer survivors is recommended.78
Risk of pregnancy-related cardiovascular complications, pre-
dominantly HF, increases after cardiotoxic cancer therapies. In
a large retrospective study79 with 847 female cancer survivors
completing 1554 pregnancies, 43 women presented with car-
diomyopathy, the majority either prior to pregnancy or 5+ months
post-pregnancy. Only three women (0.3%) developed a new
pregnancy-associated cardiomyopathy. The total cumulative AC
dose was higher in women presenting with cardiomyopathy com-
pared to the cohort who did not develop HF. Of 58 female cancer
survivors with pregnancy,80 17 (27.6%) developed new LV dysfunc-
tion (ejection fraction <50% on two successive echocardiograms),
compared to 15% in a control female cancer survivor group
without pregnancy. Risk factors included high total cumulative AC
dose, and younger age at treatment. In a recent smaller cohort of
female cancer survivors,8 four women developed overt HF during
their pregnancy (5%), and all four had history of pre-existing
cardiomyopathy. Thus, the incidence of pregnancy-induced HF was
31% (4/13) vs. 0% (0/65) in women with vs. without pre-existing
cardiomyopathy.8
In summary, the absolute risk of pregnancy-induced HF in
female cancer survivors is low, but in female cancer survivors
who received AC chemotherapy or chest radiation the risk is
higher than in healthy untreated female populations. Risk factors for
pregnancy-induced HF in female cancer survivors are summarized




















































































.. We recommend that all female cancer survivors who received
AC or chest radiation are counselled about the potential cardio-
vascular risks associated with pregnancy and are advised to have
a cardiology review including resting ECG, echocardiography, NP
measurements and risk assessment prior to all planned pregnan-
cies. Establishing NP levels either before pregnancy or early in
pregnancy and following the levels during pregnancy can help diag-
nose early haemodynamic deterioration. We recommend all female
cancer survivors who received AC or chest radiation should be
reviewed by a pregnancy heart team with clinical history, examina-
tion, NP measurement and echocardiography to assess LV function
at the end of the trimester (12–14 weeks) and a personalized
surveillance plan developed to monitor cardiovascular health dur-
ing their pregnancy. The frequency of further assessments with
NP measurement and echocardiography depend upon the pres-
ence and severity of abnormalities detected, and monitoring using
the ESC guidelines for the management of cardiovascular diseases
in pregnancy is recommended.1 Female cancer survivors identi-
fied as high risk of pregnancy-induced cardiovascular complications
should have their obstetric care delivered by a pregnancy heart
team.1
Cardiovascular risk in women receiving
chemotherapy during pregnancy
Women without known HF requiring AC chemotherapy dur-
ing pregnancy often are at higher risk and cardiac monitoring
is recommended, with delivery involving the pregnancy heart
team. There is a small population of women who present with
a new malignancy during pregnancy which requires treatment
with potentially cardiotoxic cancer therapies. This includes
pregnancy-associated breast cancer (2% of all breast cancer cases)
and Hodgkin’s lymphoma where AC chemotherapy is indicated.
There are no studies on the rate of cardiovascular complications
in this patient cohort, but the consensus and experience of the
co-authors is that these women requiring AC chemotherapy
during pregnancy are at higher risk and cardiac monitoring is
recommended and delivered by the pregnancy heart team in
collaboration with a cardio-oncology team with appropriate risk
assessment before starting chemotherapy.14 Finally, the constant
flux of new antineoplastic agents, such as immune checkpoint
inhibitors, with new cardiac side-effects that may occur unexpect-
edly, requires an infrastructure allowing fast and intense interaction
between cardiologists, oncologists and gynaecologists.
Adult congenital heart disease
and pregnancy
In the large prospective ROPAC registry, ACHD is the most
prevalent diagnosis (58%).81 Women with ACHD have a relatively
favourable pregnancy outcome, with a mortality rate of 0.2%.
However, due to the heterogeneity of this group, the type and
complexity of CHD needs to be considered. Indeed, the HF rate
was 7% for the total group and, in patients with complex CHD
this was 13%, while it was 5% and 6% for the simple and moderate
© 2021 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Risk factors for pregnancy-induced heart failure in female cancer survivors
Left ventricular dysfunction (LVEF <50%) pre-pregnancy (higher risk if LVEF <40% pre-pregnancy)
Previous AC chemotherapy (higher risk in women who received a total cumulative doxorubicin dose ≥250 mg/m2 or equivalent)
Previous chest radiation therapy (higher risk if total cumulative chest radiation dose ≥35 Gy)
Cancer diagnosis and treatment at young age (<10 years)
Time from cancer treatment to pregnancy >15 years
Recommendations for the management of pregnancy in female cancer survivors
All female cancer survivors who received AC or chest radiation should be counselled about the potential cardiovascular risks associated with
pregnancy
All female cancer survivors who received AC or chest radiation are recommended to have a cardiology review including resting
echocardiography and risk assessment prior to all planned pregnancies
All female cancer survivors who received AC or chest radiation should be reviewed with clinical history, examination and echocardiography
to assess left ventricular function at the end of the trimester of all pregnancies
All female cancer survivors who received AC or chest radiation should have personalized surveillance plan developed to monitor
cardiovascular health during their pregnancy
All female cancer survivors who received AC or chest radiation are recommended to have their obstetric care delivered by a
multidisciplinary team including an obstetrician and a cardiologist
All female cancer survivors who are at high risk of pregnancy-induced cardiovascular complications should have their obstetric care delivered
by a multidisciplinary team specialized in the care of high-risk pregnancies: the pregnancy heart team
Baseline cardiac assessment pre-chemotherapy and cardiac monitoring during chemotherapy is recommended for all women requiring AC
chemotherapy during pregnancy
All women requiring AC chemotherapy during pregnancy should have their obstetric care delivered by a multidisciplinary team specialized in
the care of high-risk pregnancies: the pregnancy heart team
AC, anthracycline; LVEF, left ventricular ejection fraction.
defects, respectively. The vast majority of these patients had their
condition treated at a very young age, creating ample opportunities
for pre-pregnancy counselling and the optimization of cardiac
status prior to pregnancy, perhaps accounting for the relatively
good outcomes.19 Maternal mortality complicates pregnancy in
0.1% of women with corrected CHD and in 0.7% with uncorrected
CHD.19,81 HF occurs in about 5% of women with corrected
CHD, and 8% of women with uncorrected CHD, of whom 3%
are solely post-partum. Signs of HF before pregnancy, pulmonary
hypertension and medication use before pregnancy were found
to be predictors for mortality or HF.82 Cyanosis is a risk factor
for maternal cardiovascular events and associated with a high
risk of miscarriage. Women with a Fontan circulation are also
at high risk and need counselling. Although, in general, patients
with regurgitant lesions often tolerate pregnancy well, severe valve
regurgitation both left- or right-sided, can cause HF. Left heart
obstruction can also cause HF, and mitral stenosis is especially not
well tolerated.83
Concerning the timing of the event of HF, in the ROPAC registry
there was a peak around the end of the second trimester (typically
women with a shunt lesion) and the second shortly after delivery
(women with diminished LV ejection fraction).84
Treatment of HF is essentially the same as outside pregnancy
but avoiding embryo/fetotoxic drugs. In patients with a systemic
right ventricle (transposition of the great arteries operated with
a Senning/Mustard procedure or congenitally corrected trans-
position of the great arteries patients), there is no evidence
that medication such as ACE-inhibitors are effective. Finally, early














































Patients with an unexpected phenotype of a cardiomyopathy
before and after pregnancy need further certification. According
to current recommendations, this is usually based on cardiac mag-
netic resonance imaging.2 In cases of uncertainty and to evaluate
differential diagnosis with potential therapeutic consequences an
endomyocardial biopsy can be helpful. Such a scenario could be in
the difficult setting of suspected post-partum cardiomyopathies in
patients who do not recover adequately over time.
Medication during pregnancy
and breastfeeding
The recently published position paper on PPCM3 summarizes in
Table 3 the safety or potential detrimental effects of common
HF medications during pregnancy and lactation. Breastfeeding is
tolerated by many women with mild HF and many drugs for HF
are not contraindicated in breastfeeding mothers and may be used
with caution.
Pregnancy induces significant changes in maternal physiology that
interfere with pharmacokinetic and pharmacodynamic actions of
the drugs (Table 2). A greater fluctuation in the unbound drug
concentration occurring during the dosing interval may potentiate
the pharmacodynamic effects at peak or reduce therapeutic effect
at trough. This is of relevance for cardiovascular drugs with direct
effect on physiological parameters (heart rate, blood pressure,
etc.). Therefore, during pregnancy it is recommended to employ
a more frequent dosing with an adjustment according to the
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Table 2 Factors affecting pharmacokinetics in
pregnancy
Cardiovascular system, lungs and blood
• Increases in plasma volume, cardiac output, stroke volume,
and heart rate
• Decreases in serum albumin concentration and serum colloid
osmotic pressure
• Increases in coagulation factors and fibrinogen
• Compression of the inferior vena cava by the uterus
• Increase in tidal volume and minute ventilation
Liver, stomach, and intestines
• Changes in oxidative liver enzymes, such as increased activity
of cytochrome P450 enzymes (e.g. CYP2D6 and CYP3A4)
• Nausea and vomiting
• Delayed gastric emptying
• Prolonged small bowel transit time
• Gastrointestinal reflux
Kidneys
• Increase in renal blood flow and glomerular filtration rate
observed pharmacodynamic effect on the mother and the foetus
(i.e. heart rate, blood pressure, international normalized ratio,
activated partial thromboplastin time, etc.).1
Conclusion
Risk stratification and management of pregnancy and the
post-partum period for women with a diagnosis of structural
heart disease and a history of HF is complex and requires the
input of a multidisciplinary team. Women with a history of
chemo-/radiotherapy for cancer or haematological malignancies
need specific pre-pregnancy assessment and counselling.
Women with a known diagnosis of a cardiomyopathy will often
require continuation of drug therapy, which has the potential to
exert adverse effects on the foetus. This position paper provides
guidance in balancing benefits and detrimental effects for the
mother and the child.
Supplementary Information
Additional supporting information may be found online in the
Supporting Information section at the end of the article.
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